Animal models of Parkinson's disease and their applications

被引:6
|
作者
Park, Hyun Jin [1 ]
Zhao, Ting Ting [1 ]
Lee, Myung Koo [1 ]
机构
[1] Chungbuk Natl Univ, Dept Pharm, Res Ctr Bioresource & Hlth, Coll Pharm, 1 Chungdae Ro, Cheongju 28644, South Korea
基金
新加坡国家研究基金会;
关键词
Parkinson's disease; neurotoxin animal models; genetic animal models; adjuvant therapeutics;
D O I
10.2147/JPRLS.S85419
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Parkinson's disease (PD) is a progressive neurodegenerative disorder that occurs mainly due to the degeneration of dopaminergic neuronal cells in the substantia nigra. L-3,4-Dihydroxyphenylalanine (L-DOPA) is the most effective known therapy for PD. However, chronic L-DOPA administration results in a loss of drug efficacy and irreversible adverse effects, including L-DOPA-induced dyskinesia, affective disorders, and cognitive function disorders. To study the motor and non-motor symptomatic dysfunctions in PD, neurotoxin and genetic animal models of PD have been widely applied. However, these animal models do not exhibit all of the pathophysiological symptoms of PD. Regardless, neurotoxin rat and mouse models of PD have been commonly used in the development of bioactive components from natural herbal medicines. Here, the main animal models of PD and their applications have been introduced in order to aid the development of therapeutic and adjuvant agents.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?
    Weidong Le
    Pavani Sayana
    Joseph Jankovic
    Neurotherapeutics, 2014, 11 : 92 - 110
  • [32] Animal models of Parkinson's disease: Similarities and differences between the disease and models
    Hattori, Nobutaka
    Sato, Shigeto
    NEUROPATHOLOGY, 2007, 27 (05) : 479 - 483
  • [33] Photobiomodulation for Parkinson's Disease in Animal Models: A Systematic Review
    Salehpour, Farzad
    Hamblin, Michael R.
    BIOMOLECULES, 2020, 10 (04)
  • [34] Neuroprotection by immunomodulatory agents in animal models of Parkinson's disease
    Martinez, Bridget
    Peplow, Philip V.
    NEURAL REGENERATION RESEARCH, 2018, 13 (09) : 1493 - 1506
  • [35] Therapeutic Effects of Hydrogen in Animal Models of Parkinson's Disease
    Fujita, Kyota
    Nakabeppu, Yusaku
    Noda, Mami
    PARKINSONS DISEASE, 2011, 2011
  • [36] Somatic gene therapy in animal models of Parkinson's disease
    Bauer, M
    Ueffing, M
    Meitinger, T
    Gasser, T
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1999, (55): : 131 - 147
  • [37] Neuroprotective Effects of Temsirolimus in Animal Models of Parkinson's Disease
    Siracusa, Rosalba
    Paterniti, Irene
    Cordaro, Marika
    Crupi, Rosalia
    Bruschetta, Giuseppe
    Campolo, Michela
    Cuzzocrea, Salvatore
    Esposito, Emanuela
    MOLECULAR NEUROBIOLOGY, 2018, 55 (03) : 2403 - 2419
  • [38] Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease
    Trancikova, Alzbeta
    Tsika, Elpida
    Moore, Darren J.
    ANTIOXIDANTS & REDOX SIGNALING, 2012, 16 (09) : 896 - 919
  • [39] Classic animal models of Parkinson's disease: a historical perspective
    Hamadjida, Adjia
    Frouni, Imane
    Kwan, Cynthia
    Huot, Philippe
    BEHAVIOURAL PHARMACOLOGY, 2019, 30 (04): : 291 - 310
  • [40] Evaluation of motor disorders in animal models of Parkinson's disease
    Campos-Romo, A.
    REVISTA DE NEUROLOGIA, 2008, 46 (03) : 167 - 174